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Abstract
Carboxypeptidase M (CPM) is an extracellular glycosylphosphatidyl-
inositol-anchored membrane glycoprotein, which removes the C-
terminal basic residues, lysine and arginine, from peptides and pro-
teins at neutral pH. CPM plays an important role in the control of
peptide hormones and growth factor activity on the cell surface. The
present study was carried out to clone and express human CPM in the
yeast Pichia pastoris in order to evaluate the importance of this
enzyme in physiological and pathological processes. The cDNA for
the enzyme was amplified from total placental RNA by RT-PCR and
cloned in the vector pPIC9, which uses the methanol oxidase promoter
and drives the expression of high levels of heterologous proteins in P.
pastoris. The cpm gene, after cloning and transfection, was integrated
into the yeast genome, which produced the active protein. The recom-
binant protein was secreted into the medium and the enzymatic
activity was measured using the fluorescent substrate dansyl-Ala-Arg.
The enzyme was purified by a two-step protocol including gel filtra-
tion and ion-exchange chromatography, resulting in a 1753-fold
purified active protein (16474 RFU mg protein-1 min-1). This purifica-
tion protocol permitted us to obtain 410 mg of the purified protein per
liter of fermentation medium. SDS-PAGE showed that recombinant
CPM migrated as a single band with a molecular mass similar to that
of native placental enzyme (62 kDa), suggesting that the expression of
a glycosylated protein had occurred. These results demonstrate for the
first time the establishment of a method using P. pastoris to express
human CPM necessary to the development of specific antibodies and
antagonists, and the analysis of the involvement of this peptidase in
different physiological and pathological processes
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Introduction
Carboxypeptidase M (CPM) is an extra-
cellular glycosylphosphatidyl-inositol-an-
chored membrane glycoprotein. This pro-
tein is a member of the CPN/E subfamily of
zinc metallo-carboxypeptidase. It specifically
removes C-terminal basic residues such as
lysine and arginine from peptides and from
proteins at neutral pH (1-4). The highest
levels of CPM have been found in human
lung and placenta, but significant amounts
are present in kidney, blood vessels, intes-
tine, brain, and peripheral nerves (1,5-7).
CPM has been found also in soluble form in
various body fluids, including amniotic fluid,
seminal plasma and urine (5,8,9). Due to its
wide distribution in a variety of tissues, it is
believed to play important roles in the con-
trol of peptide hormone and growth factor
activity on the cell surface, and in the mem-
brane-localized degradation of extracellular
proteins (10).
By removing the C-terminal Arg residue
of the intact kinins (and related peptides),
CPM can switch the receptor specificity (11),
inactivating the agonist for the B2 receptor
and concomitantly producing an agonist for
the B1 receptor (1). Recent results from our
group have shown that the kinin B1 receptor
is important for neutrophil migration into
inflamed tissues (12,13) and for glucose/
insulin homeostasis (Araujo RC, unpublished
data). Furthermore, CPM is recognized by
antibodies that detect cell surface antigens
on macrophages and is strongly induced in
the differentiation of monocytes to macro-
phages (14). Therefore, the mechanism for
neutrophil migration could be dependent on
the CPM present in the cell membrane of
macrophages, indicating a relevant role of
this enzyme at sites of inflammation. In ad-
dition, the conversion of agonistic activity
was shown to result in an enhanced and
prolonged output of nitric oxide in response
to bradykinin or kallidin in cytokine-stimu-
lated human lung microvascular endothelial
cells (15). By cloning the cDNA from differ-
ent human tissues, we could determine the
molecular structure (16) and show the pres-
ence of alternatively spliced messages for
CPM. Furthermore, we could also show that
the expression of this carboxypeptidase in
tumor tissues is differently regulated, rais-
ing the question of the role of this enzyme in
cancer (16). Thus, taking into account the
function played by kinins and nitric oxide in
inflammatory diseases and cancer (11), and
the fact that specific inhibitors of this car-
boxypeptidase are still lacking, CPM might
be an important target for the development
of new drugs to treat these pathologies.
Recently, a human CPM (hCPM) was
expressed by using a system based on bacu-
lovirus-infected insect cells (Sf9) (17). The
cited study aimed to identify the membrane-
anchor signal and the glycosylphosphatidyl-
inositol attachment site and to investigate
the roles of the two conserved glutamic acid
residues, Glu260 and Glu264, in kinetic param-
eters and in protein stability. Furthermore,
the same group determined the crystal struc-
ture of the human enzyme (18).
Therefore, the objective of the present
study was to obtain an active glycosylated
protein using the expression system of the
yeast Pichia pastoris. This system has sev-
eral advantages, including the use of the
alcohol oxidase I gene promoter, the ability
to stably integrate expression plasmids at
specific sites, the ability of the cells to be
cultivated at high density, and a simplified
purification procedure for secreted heterolo-
gous proteins. Moreover, similar to mam-
malian and insect cells, P. pastoris can carry
out certain co- and post-translational modi-
fications of foreign proteins (19,20). The
results described in the present report dem-
onstrate a high level of expression of the
active recombinant hCPM with a molecular
mass similar to the native glycoprotein (62
kDa), indicating that the P. pastoris expres-
sion system can be useful for the production
of active CPM at relevant levels.
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Material and Methods
Enzymes, primers and vectors for molec-
ular biology procedures were purchased from
Invitrogen (Carlsbad, CA, USA) and Pro-
mega (Madison, WI, USA). The dansyl-Ala-
Arg substrate was from Bachem (King of
Prussia, PA, USA). DNA sequencing was
performed using an ABI377 sequencer (Ap-
plied Biosystems, Foster City, CA, USA).
The Amicon Ultra 30,000 MWCO mem-
brane was from Millipore (Billerica, MA,
USA), and the Superdex 200 HR 10/30 and
Mono Q HR 5/5 columns were from Amer-
sham Biosciences (Piscataway, NJ, USA).
RNA extraction and reverse transcription
polymerase chain reaction
Total RNA from human placenta was
isolated using the Trizol reagent according
to the manufacturer’s protocol and its purity
was evaluated by electrophoresis on 1% aga-
rose gel. Contamination of RNA samples
with genomic DNA was avoided by treat-
ment for 1 h at 37ºC with 1 U RNAse-free/
DNAse I per 2 µg RNA. For the same amount
of RNA, the reaction also contained 20 U
RnaseOUT-Rnase inhibitor and 3 mM
MgCl2. After incubation, samples were
heated to 95ºC and immediately chilled on
ice for DNAse I denaturation. Reverse trans-
cription was performed using 2 µg total RNA,
200 U Moloney murine leukemia virus II
reverse transcriptase, 5 mM DTT, 50 ng
random hexamer primers, 1X PCR buffer,
0.5 mM dNTPs, and 3 mM MgCl2. Reac-
tions were carried out at 20ºC for 10 min,
42ºC for 45 min, 95ºC for 5 min, and 4ºC for
10 min. The resulting cDNA from the hu-
man placenta was then used for PCR which
was performed with 500 ng cDNA. The PCR
mixture contained 0.5 µM concentrations of
sense (hCPM5 5'-GAATTCTTGCTGCCTT
TGGTAGCTGC) and antisense (CPMAS2
5'-GCGGCCGCTTATTTGAAGAATAT
GTGC) primers, which contained added sites
for the restriction enzymes EcoRI and NotI,
respectively, 2 U platinum TaqDNA poly-
merase, 1.5 mM MgCl2, 50 mM KCl, and 20
mM Tris-HCl, pH 8.3, in a 50-µL volume.
PCR amplification was performed by incu-
bating the samples at 94ºC for 1 min, fol-
lowed by 30 cycles at 94ºC for 1 min, and at
60ºC for 90 s, with a final extension at 72ºC
for 7 min. At the end of amplification,
samples were submitted to electrophoresis
on 1% agarose gel with a 100-bp DNA lad-
der as a size marker. The amplified bands of
1313 bp were visualized by ethidium bro-
mide staining.
Construction of expression vector pPIC9-cpm
The PCR-amplified fragment encoding
hCPM was cloned into the pGEM-T-Easy
(Promega) cloning vector and subjected to
double-stranded DNA sequencing (ABI 377,
Applied Biosystems) After EcoRI-NotI di-
gestion, the cpm gene was cloned in frame
into the pPIC9 (Invitrogen) vector between
the EcoRI (5' end) and NotI (3' end) restric-
tion sites to generate the plasmid pPIC9-
cpm.
Transformation of Pichia pastoris and
selection of high-level expression colonies
The following culture media used for
transformation of P. pastoris, selection of
recombinant clones, and expression of CPM
were prepared according to manufacturer
recommendations (Invitrogen): minimal dex-
trose medium (MD), minimal methanol me-
dium (MM), buffered glycerol-complex
medium (BMGY), and buffered minimal
methanol (BMMY). For cultures in liquid
BMMY, which contain methanol as an in-
ducer and carbon source, methanol was added
every 24 h to a final concentration of 0.5%
(v/v). All cultures were carried out at 30oC.
The pPIC9-cpm construct (10 µg) was lin-
earized with BglII and transformed into P.
pastoris wild-type strain GS115 (Invitrogen)
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by electroporation at 25 µF, 400 Ω, and 1500
V using a Bio-Rad (Hercules, CA, USA)
GenePulser. Immediately after pulsing, 1
mL cold 1 M sorbitol was added to the P.
pastoris cells, and plated onto MD contain-
ing 1 M sorbitol. After cultivation, all trans-
formants were patched or replica plated onto
both MM and MD plates to select the colo-
nies growing more slowly in MM than in
MD, and these colonies were cultivated in
liquid BMMY. To analyze cpm gene inte-
gration into the P. pastoris genome, genom-
ic DNA was isolated from different clones
and integration was confirmed by PCR us-
ing the same cloning primers. CPM activity
of positive clones in the BMMY supernatant
was measured with the dansyl-Ala-Arg sub-
strate as previously described (21). The clone
presenting the highest CPM activity was
inoculated into 100 mL BMGY and cultured
for 1 day. The cells were then collected by
centrifugation and resuspended in 500 mL
BMMY. Every day (0, 24, 48, 72, and 96 h),
just before the addition of 0.5% methanol,
an aliquot of the medium was collected to
measure CPM activity and protein concen-
tration.
Purification of recombinant
carboxypeptidase M
The CPM secreted in the supernatant was
purified by a two-step procedure consisting
of gel filtration and ion-exchange chroma-
tography. Briefly, the expression medium
was concentrated on an Amicon concentra-
tor with an Amicon Ultra 30,000 MWCO
membrane (Millipore), and loaded on a
Superdex 200 HR 10/30 column (Amer-
sham Biosciences) equilibrated with 50 mM
Na-phosphate buffer, pH 7, containing 0.15
M NaCl. The column was eluted with the
equilibration buffer at a flow rate 0.8 mL/
min, and 0.5-mL fractions were collected
and assayed for CPM activity. The effluent
from the gel filtration column containing
enzyme activity was combined and loaded
onto a Mono Q HR 5/5 column (Amersham
Biosciences) equilibrated with 50 mM Tris-
HCl buffer, pH 8. The column was washed
with equilibration buffer and then eluted
with a linear gradient of 0 to 1 M NaCl in the
same buffer. Proteins were detected by UV
absorption at 280 nm, 0.5-mL fractions were
collected and assayed for CPM activity.
Protein concentration was determined by
the dye-binding method of Bradford (22)
using bovine serum albumin as a standard.
Results and Discussion
Analysis of transformed clones and
expression of human carboxypeptidase M
Total RNA from human placenta was
isolated and submitted to the reverse trans-
cription. The resultant cDNA was then used
for PCR and yielded a 1313-bp DNA frag-
ment containing the whole coding region
with the expected sequence, except for one
base change at position 1158 (T → A; data
not shown). However, this base alteration
does not lead to a change in the amino acid
sequence of the generated protein. After di-
gestion with EcoRI-NotI restriction enzymes,
the cpm gene was cloned in frame in the
pPIC9. The generated plasmid pPIC9-cpm
containing the hCPM gene was transformed
into the P. pastoris wild-type strain GS115.
Some of the colonies selected on MD plates
(10 of 34 colonies) were tested by PCR to
confirm the integration of the CPM coding
region into the P. pastoris genome and six
positive clones were selected. The clone with
the highest activity (9.4 RFU min-1 mg pro-
tein-1) and one negative control, pPIC9 (with-
out the insert), were initially inoculated into
BMGY and later into BMMY. The cells and
the supernatant of these clones were then
collected by centrifugation, CPM activity
was measured and protein concentration was
determined. As shown in Figure 1, carbox-
ypeptidase activity was detected at high lev-
els in the supernatant of the positive clone.
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Figure 2 shows the levels of the total carbox-
ypeptidase activity at different times. As
observed, CPM activity increased in the
medium in a time-dependent manner. The
advantage of expressing heterologous pro-
teins as secreted proteins is that P. pastoris
secretes very low levels of native proteins.
This, combined with the very low amount of
protein in the minimal Pichia growth medi-
um, means that the medium serves as the
first step in the purification of the protein
(19).
Purification of human carboxypeptidase M
The supernatant was concentrated
through an Amicon membrane and submit-
ted to gel filtration chromatography (Super-
dex 200 HR 10/30). Protein elution was
monitored by measuring the absorbance at
280 nm and the carboxypeptidase activity
was evaluated with the substrate dansyl-
Ala-Arg. Protein eluted from the column
showed one major peak of activity with a
molecular mass estimated between 40 and
90 kDa (Figure 3A). The fractions corre-
sponding to this major peak were pooled (P)
and submitted to SDS-PAGE. The results
showed the presence of three main bands in
the gel (Figure 3B). The active fraction was
submitted to ion-exchange chromatography
(Mono Q 5/5) which resulted in only one
peak of activity and a band in SDS-PAGE
around 62-70 kDa (Figure 4), similar to the
62 kDa corresponding to the native placental
protein. This small difference in molecular
mass could be attributed to the partial cleav-
age produced by the P. pastoris STE13 pro-
tease in the recombinant protein, leaving
four additional amino acids (EAEA) at the
N-terminal region (23). Another reason could
be the differences in the number and type of
sugar units added to the yeast-secreted pro-
teins compared with human proteins (24).
The purification steps resulted in 1753-
fold purification of recombinant hCPM. The
specific activity of the purified enzyme was
Figure 1. Expression of recom-
binant hCPM in the control and
transformed (hCPM) clones of
Pichia pastoris 24 h after inocu-
lation into buffered glycerol-
complex medium. The yeast
cells (y) and the supernatant (s)
were separated by centrifuga-
tion and assayed for CPM activ-
ity with dansil-Ala-Arg as sub-
strate. hCPM = human carbox-
ypeptidase M; RFU = relative flu-
orescence units. *P < 0.01 com-
pared to the supernatant of the
control clone (t-test).
Figure 2. Carboxypeptidase M
activity in the culture superna-
tant of the GS115-CPM strain.
Cells were induced in buffered
minimal methanol and the activ-
ity was evaluated with the sub-
strate dansil-Ala-Arg at different
times. RFU = relative fluores-
cence units. *P < 0.05 and **P <
0.01 compared to the 24-h cul-
ture (t-test).
Figure 3. A, Gel filtration of recombinant human carboxypeptidase M (CPM). The concen-
trated supernatant (3.05 mg/mL in 2 mL) was loaded onto a Superdex 200 HR 10/30 column
in the FPLC system. The column was equilibrated with 50 mM Na-phosphate buffer, pH 7,
containing 0.15 M NaCl and eluted with the equilibration buffer at a flow rate of 0.8 mL/min.
Fractions of 0.5 mL were collected and assayed for CPM activity. RFU = relative fluores-
cence units. B, SDS-PAGE (12%) of pooled fractions containing CPM activity (P). M,
molecular mass markers (Bench Mark Protein Ladder, Invitrogen).
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16474 RFU mg-1 min-1 using dansyl-Ala-
Arg as substrate (Table 1). The very low
levels of specific activity observed for the
crude supernatant when compared to the
purified enzyme may be explained by the
presence of inhibitors of the enzyme in the
fermentation medium. Some salts added to
the medium at high concentrations are able
to inhibit CPM and probably are separated
from the enzyme during the purification pro-
cess, causing a large increase in specific and
total activities.
The latest achievements in the expression
system of P. pastoris have changed deeply the
methodology used to express heterologous
proteins, increasing the expression levels and
bioactivity of the latter. In addition, the great
success of P. pastoris is related to the fact that
this organism is a eukaryote, capable to ex-
press proteins with post-translational modifi-
cations, sometimes essential for proper func-
tion. A further benefit of the P. pastoris system
is that strong promoters are available to drive
the expression of the foreign gene(s), thus
enabling production of large amounts of the
target protein(s) with relative technical ease
and at a lower cost than most other eukaryotic
systems (25).
The results shown here demonstrate the
establishment of a method using P. pastoris
to express CPM in high yield of purified
enzyme, i.e., 410 mg/L of fermentation cul-
ture. The expression levels of the hCPM in
Pichia obtained in the present study was
much higher (around 10-fold) when com-
pared to the published expression system
using baculovirus-infected insect cells, about
30-40 mg/L of recombinant mutant CPM in
the culture medium (17). Some investiga-
tors, using the same system, have also de-
scribed a similar recovery for the enzyme
tannin acyl hydrolase (25), and even higher
recoveries for the enzyme lipase/acyltrans-
ferase from Candida parapsilosis (EC 3.1.1.3)
(26), and for the tetanus toxin fragment C
(24,27), highlighting the potential of this
technique to express high yield of heterolo-
gous proteins.
The present data show that we developed a
methodology that permits the production of
large amounts of the CPM enzyme, necessary
for the development of specific antibodies and
antagonists and for the analysis of the involve-
ment of this peptidase in different physiologi-
cal and pathological processes.
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Figure 4. A, Ion-exchange chromatography. A pool of effluent containing enzyme activity
(0.28 mg/mL in 1.5 mL) obtained by gel filtration (Figure 3) was loaded onto a Mono Q HR 5/
5 column equilibrated with 50 mM Tris-HCl buffer, pH 8. The column was washed with
equilibration buffer and then eluted with a linear gradient (0 to 1 M) NaCl in the same buffer.
Proteins were detected by UV absorption at 280 nm. Fractions of 0.5 mL were collected and
assayed for carboxypeptidase M activity. RFU = relative fluorescence units. B, SDS-PAGE
(12%) of pooled active fractions. M, molecular mass markers (Bench Mark Protein Ladder,
Invitrogen). Human carboxypeptidase M (hCPM) appears as a diffuse band because it is a
glycoprotein.
Table 1. Purification of recombinant hCPM from 1 mL of fermentation supernatant.
Step Protein Total Specific Purification
(mg) activity* activity** (X-fold)
Supernatant 6.10 57.3 9.4 1
Superdex 200 HR 0.86 2077.0 2415 257
Mono Q 0.41 6754.3 16474 1753
*RFU/min. **RFU min-1 mg protein-1. RFU = relative fluorescence units; hCPM =
human carboxypeptidase M. Purification = Mono Q specific activity/supernatant spe-
cific activity.
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